Clinical Trials
167 trialsComparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Alliance for Clinical Trials in Oncology
Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast Cancer
Fudan University
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)
Memorial Sloan Kettering Cancer Center
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
NRG Oncology
CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer(Cinnamon)
Fudan University
CABA-DOC
Gustave Roussy, Cancer Campus, Grand Paris
SHINE
Sun Yat-sen University
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
Ruijin Hospital
REINFORCE
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
COMET
Intergroupe Francophone de Cancerologie Thoracique
PANSY
Fudan University
EMERALD
Japan Breast Cancer Research Group
STAMPEDE2
University College, London
PRECIOUS
Japan Breast Cancer Research Group
SALTORL
Groupe Oncologie Radiotherapie Tete et Cou
Pharmaco-economic Study of a Second Line Treatment in Advanced Non Small Cell Lung Cancer
University Hospital, Limoges
TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer
Peking Union Medical College Hospital
Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor
Fudan University
ProBio
Karolinska Institutet
EURTAC
Spanish Lung Cancer Group
ARASAFE
Jena University Hospital
Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer
Mayo Clinic
Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients
Fudan University
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
UNICANCER
PANTHER
Karolinska University Hospital
GECP-SCAT
Spanish Lung Cancer Group
PEACE1
UNICANCER
FLOT5
Krankenhaus Nordwest
PREVENT
Krankenhaus Nordwest
Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline
Huazhong University of Science and Technology
Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC
Shanghai Junshi Bioscience Co., Ltd.
Detect V / CHEVENDO (Chemo vs. Endo)
University of Ulm
NEOSAMBA
Latin American Cooperative Oncology Group
Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:
Xijing Hospital of Digestive Diseases
ESOPEC
University Hospital Schleswig-Holstein
NEOPCOSCC
Hospital of Stomatology, Wuhan University
Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH
Asan Medical Center
TavIx
UNICANCER
Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
BREC
Spanish Lung Cancer Group
Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)
Sun Yat-sen University
CLOVER
Fudan University
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
Beijing Tongren Hospital
Perioperative FLOT vs Adjuvant XELOX for CA Stomach
Chinese University of Hong Kong
Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
The First Affiliated Hospital with Nanjing Medical University
Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
Sun Yat-sen University
EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
Fudan University
Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
Nanfang Hospital, Southern Medical University